
Opinion|Videos|May 7, 2024
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO
Author(s)Marion R. Munk, MD, PhD
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Ophthalmic care uncommon after tamoxifen initiation
2
FDA requires NAION warning across the GLP-1 receptor agonist class
3
Retinal gene therapy in 2026: 13 milestones from January through October
4
Training refractive surgeons and expanding access to eye surgery
5
















